

Supplementary material for:

Antioxidant Cuttlefish Collagen Hydrolysate Against Ethyl Carbamate-induced Oxidative Damage

Bowei Du^{a&}, Guiya Deng^{a&}, Fakhar Zaman^a, Hui Ma^a, Xuejuan Li^b, Jialiang Chen^c, Tianyu Li^{d*} and Yaqin

Huang^{a*}

^a Beijing Laboratory of Biomedical Materials, Key Laboratory of Biomedical Materials of Natural Macromolecules (Beijing University of Chemical Technology), Ministry of Education, Beijing University of Chemical Technology, Beijing 100029, People's Republic of China.

^b Rongcheng Lanrun Biological Technology Co., Ltd, Rongcheng 264309, People's Republic of China.

^c Department of Graduate School, Beijing University of Chinese Medicine, Beijing 100029, People's Republic of China.

^d Department of Biomedical Engineering, Columbia University, New York, NY, 10027, USA.

* Correspondence: Yaqin Huang, huangyq@mail.buct.edu.cn; Tianyu Li, tl2999@columbia.edu.

& These authors contributed equally to this work and should be considered co-first authors.

Table S1 Experimental values and coded levels of variables for Box-Behnken designs (BBD)

| Coded variables | | Low level (-1) | Medium level (0) | High level (+1) |
|-----------------|------------------|----------------|------------------|-----------------|
| X ₁ | Temperature (°C) | 40 | 45 | 50 |
| X ₂ | pH | 7 | 8 | 9 |
| X ₃ | Enzyme (U/g) | 6500 | 7000 | 7500 |

Table S2 Box-Behnken designs (BBD) and response

| Run | Variables ^a | | | Y: DPPH radical scavenging rate (%) |
|-----|------------------------------|---------------------|-------------------------|-------------------------------------|
| | X ₁ : Temperature | X ₂ : pH | X ₃ : Enzyme | |
| 1 | -1 | 1 | 0 | 67.58 |
| 2 | 0 | 1 | -1 | 62.41 |
| 3 | -1 | -1 | 0 | 70.93 |
| 4 | 0 | 1 | 1 | 68.49 |
| 5 | 1 | -1 | 0 | 69.61 |
| 6 | -1 | 0 | -1 | 64.44 |
| 7 | 0 | -1 | 1 | 73.42 |
| 8 | 1 | 0 | 1 | 69.23 |
| 9 | 1 | 1 | 0 | 64.92 |
| 10 | -1 | 0 | 1 | 72.61 |
| 11 | 0 | -1 | -1 | 66.65 |
| 12 | 1 | 0 | -1 | 64.96 |
| 13 | 0 | 0 | 0 | 78.82 |
| 14 | 0 | 0 | 0 | 78.19 |
| 15 | 0 | 0 | 0 | 78.62 |
| 16 | 0 | 0 | 0 | 78.46 |
| 17 | 0 | 0 | 0 | 79.09 |

^a Low level (-1) Medium level (0) High level (+1)

Table S3 Up- and down-regulated genes in HepG2 cells treated with CCH or EC

| Gene symbol | Gene description | Log ₂ fold change (compared to control group) ^a | |
|-------------|--|---|--------|
| | | EC | CCH-EC |
| AKR1C2 | Aldo-keto reductase family 1, member C2 | +5.47 | +4.21 |
| APOE | Apolipoprotein E | +0.47 | +1.21 |
| ATOX1 | ATX1 antioxidant protein 1 homolog (yeast) | +1.74 | +0.48 |
| BAG2 | BCL2-associated athanogene 2 | +1.48 | +0.22 |
| BNIP3 | BCL2/adenovirus E1B 19 kDa interacting protein 3 | -0.52 | +0.21 |
| CAT | Catalase | +2.48 | +2.22 |
| CCL5 | Chemokine (C-C motif) ligand 5 | -0.62 | -0.91 |
| CCS | Copper chaperone for superoxide dismutase | +3.49 | +2.54 |
| DHCR24 | 24-dehydrocholesterol reductase | +2.48 | +1.22 |
| DUSP1 | Dual specificity phosphatase 1 | +2.78 | +1.52 |
| EPX | Eosinophil peroxidase | +4.47 | +4.16 |
| FHL2 | Four and a half LIM domains 2 | +0.48 | +0.22 |
| FOXM1 | Forkhead box M1 | +1.48 | +0.22 |
| FTH1 | Ferritin, heavy polypeptide 1 | +0.07 | +0.47 |
| GCLC | Glutamate-cysteine ligase, catalytic subunit | +0.48 | +0.22 |
| GCLM | Glutamate-cysteine ligase, modifier subunit | +2.64 | +1.48 |
| GLA | Galactosidase, alpha | +1.48 | -0.14 |
| GPX1 | Glutathione peroxidase 1 | +0.47 | -0.78 |
| GPX3 | Glutathione peroxidase 3 | +4.48 | +4.22 |
| GPX4 | Glutathione peroxidase 4 | +1.48 | +1.21 |
| GSR | Glutathione reductase | +0.48 | +1.21 |
| GSS | Glutathione synthetase | -0.08 | +0.65 |
| GSTP1 | Glutathione S-transferase pi 1 | -0.53 | -0.78 |
| GSTZ1 | Glutathione transferase zeta 1 | +0.48 | +0.23 |
| HMOX1 | Heme oxygenase (decycling) 1 | -2.53 | -0.78 |
| HSP90AA1 | Heat shock protein 90 kDa α , class A member 1 | +1.48 | +0.23 |
| HSPA1A | Heat shock 70 kDa protein 1A | +1.47 | +0.98 |
| LHPP | Phospholysine phosphohistidine inorganic pyrophosphate phosphatase | -0.53 | -0.78 |

| | | | |
|---------|---|-------|-------|
| MB | Myoglobin | -4.55 | -1.78 |
| MBL2 | Mannose-binding lectin (protein C) 2, soluble | +4.07 | +3.21 |
| MPV17 | MpV17 mitochondrial inner membrane protein | +0.48 | +0.22 |
| MSRA | Methionine sulfoxide reductase A | +5.48 | +4.22 |
| MT3 | Metallothionein 3 | +1.53 | +1.22 |
| NCF2 | Neutrophil cytosolic factor 2 | -0.52 | -1.78 |
| NCOA7 | Nuclear receptor coactivator 7 | +0.48 | -0.78 |
| NOX5 | NADPH oxidase, EF-hand calcium binding domain 5 | +4.47 | -5.84 |
| NQO1 | NAD(P)H dehydrogenase, quinone 1 | +0.47 | -0.80 |
| NUDT1 | Nucleoside diphosphate linked moiety X-type motif 1 | +0.48 | +0.22 |
| PDLIM1 | PDZ and LIM domain 1 | -1.53 | -0.78 |
| PRDX1 | Peroxiredoxin 1 | +0.71 | +0.45 |
| PRDX2 | Peroxiredoxin 2 | -0.53 | -0.79 |
| PRDX4 | Peroxiredoxin 4 | +0.46 | +0.21 |
| PRDX6 | Peroxiredoxin 6 | +0.47 | +0.20 |
| PRNP | Prion protein | +2.48 | +1.22 |
| PTGR1 | Prostaglandin reductase 1 | +1.48 | +1.22 |
| PTGS1 | Prostaglandin-endoperoxide synthase 1 | +1.48 | +0.22 |
| PTGS2 | Prostaglandin-endoperoxide synthase 2 | -0.99 | -1.25 |
| RNF7 | Ring finger protein 7 | +2.70 | +1.46 |
| SEPP1 | Selenoprotein P, plasma, 1 | +0.07 | -0.19 |
| SIRT2 | Sirtuin 2 | +3.48 | +2.22 |
| SLC7A11 | Solute carrier family 7, member 11 | +3.48 | +2.21 |
| SOD1 | Superoxide dismutase 1, soluble | +0.74 | +0.50 |
| SOD2 | Superoxide dismutase 2, mitochondrial | -0.52 | -0.78 |
| SOD3 | Superoxide dismutase 3, extracellular | +5.47 | +4.22 |
| SPINK1 | Serine peptidase inhibitor, Kazal type 1 | +1.46 | +3.21 |
| SQSTM1 | Sequestosome 1 | +0.97 | +0.70 |
| SRXN1 | Sulfiredoxin 1 | +2.48 | +2.22 |
| TPO | Thyroid peroxidase | +5.48 | +4.22 |
| TRAPP6A | Trafficking protein particle complex 6A | +2.48 | +1.22 |
| TXN | Thioredoxin | +0.47 | +0.22 |
| TXNRD1 | Thioredoxin reductase 1 | +0.49 | +0.21 |

| | | | |
|--------|--|-------|-------|
| TXNRD2 | Thioredoxin reductase 2 | -1.51 | -1.77 |
| UCP2 | Uncoupling protein 2 (mitochondrial, proton carrier) | +3.47 | +2.22 |
| VIMP | VCP-interacting membrane protein | +1.49 | +1.22 |

^a A gene was defined as differentially expressed gene only when it was up- or down-regulated more than 1.5-fold changes compared to control.

Table S4 Gene Ontology (GO) biological processes (BP) of enriched genes that were differentially expressed in HepG2 cells treated with CCH or EC

| GO biological process | Enriched genes | |
|---|---|--|
| | EC | CCH-EC |
| response to oxidative stress [GO:0006979] | ATOX1/CAT/CCS/DHCR24/DUSP1/EPX/GCLM/GPX3/HMOX1/MB/MBL2/MSRA/MT3/NOX5/PDLIM1/PRNP/SIRT2/SLC7A11/SOD3/SRXN1/TPO/TXNRD2/UCP2 (23/26) | CAT/CCS/DUSP1/EPX/GPX3/MB/MBL2/MSRA/NCF2/NOX5/SIRT2/SLC7A11/SOD3/SRXN1/TPO/TXNRD2/UCP2 (17/19) |
| cellular oxidant detoxification [GO:0098869] | CAT/CCS/EPX/GPX3/MT3/SOD3/SRXN1/TPO/TXNRD2 (9/26) | CAT/CCS/EPX/GPX3/SOD3/SRXN1/TPO/TXNRD2 (8/19) |
| cellular detoxification [GO:1990748] | CAT/CCS/EPX/GPX3/MT3/SOD3/SRXN1/TPO/TXNRD2 (9/26) | CAT/CCS/EPX/GPX3/SOD3/SRXN1/TPO/TXNRD2 (8/19) |
| Detoxification [GO:0098754] | CAT/CCS/EPX/GPX3/MT3/SOD3/SRXN1/TPO/TXNRD2 (9/26) | CAT/CCS/EPX/GPX3/SOD3/SRXN1/TPO/TXNRD2 (8/19) |
| cellular response to oxidative stress [GO:0034599] | CAT/CCS/GPX3/HMOX1/MT3/MSRA/NOX5/SIRT2/SLC7A11/SOD3/SRXN1/TXNRD2 (2/12/26) | CAT/CCS/GPX3/MSRA/NCF2/NOX5/SIRT2/SLC7A11/SOD3/SRXN1/TXNRD2 (D2/11/19) |
| cellular response to toxic substance [GO:0097237] | CAT/CCS/EPX/GPX3/HMOX1/MT3/SOD3/SRXN1/TPO/TXNRD2 (10/26) | CAT/CCS/EPX/GPX3/SOD3/SRXN1/TPO/TXNRD2 (8/19) |
| response to reactive oxygen species [GO:0000302] | CAT/CCS/DUSP1/HMOX1/MB/MT3/SOD3/TXNRD2/UCP2 (9/26) | CAT/CCS/DUSP1/MB/SOD3/TXNRD2/UCP2 (7/19) |
| reactive oxygen species metabolic process [GO:0072593] | CAT/CCS/EPX/GPX3/MT3/NOX5/SIRT2/SOD3/TPO (9/26) | CAT/CCS/EPX/GPX3/NCF2/NOX5/SI RT2/SOD3/TPO (9/19) |
| response to toxic substance [GO:0009636] | MT3/HMOX1/SOD3/TPO/DUSP1/EPX/CA T/SLC7A11/CCS/TXNRD2/MB/GPX3/SRX N1 (13/26) | SOD3/TPO/DUSP1/EPX/CAT/SLC7A11/CCS/TXNRD2/MB/GPX3/SRXN1 (11/19) |

| | | |
|---|--|---|
| oxidation-reduction process [GO:0055114] | MT3/HMOX1/SOD3/TPO/DHCR24/EPX/C AT/AKR1C2/CCS/MSRA/TXNRD2/GPX3/ NOX5/SRXN1 (14/26) | SOD3/TPO/NCF2EPX/CAT/AKR1C2/ CCS/MSRA/TXNRD2/GPX3/NOX5/SR XN1 (12/19) |
|---|--|---|




Fig S1 Effect of single-factor including (a) enzymolysis temperature, (b) enzymolysis time, (c) enzyme addition, and (d) substrate concentration on DPPH radical scavenging activity.




Fig S2 Surface plots for DPPH scavenging of CCH. (a) Effect of temperature and pH on DPPH Scavenging of CCH. (b) Effect of enzyme quantity and temperature on DPPH scavenging of CCH. (c) Effect of enzyme concentration and pH on DPPH scavenging of CCH. (d) Actual antioxidant capability versus model predicted the antioxidant capability of CCH. (e) Desirability plots of variables for maximum antioxidant capability.




Fig S3 Results from MS/MS spectra for the five major peptides in CCH. (a) MS/MS with the parent ion m/z 300.7. (b) MS/MS with the parent ion m/z 472.7. (c) MS/MS with the parent ion m/z 474.2. (d) MS/MS with the parent ion m/z 563.3. (e) MS/MS with the parent ion m/z 566.8.




Fig S4 Cell cytotoxicity of HepG2 cells (a) treated with EC and (b) induced by CCH in different concentrations.





Fig S5 Gene Ontology (GO) classification map of cells treated with (a) EC and (b) CCH-EC.




Fig S6 The cell cycle and apoptosis of HepG2 cells treated with 65 mM EC and CCH.